Eli Lilly: Searching for New Tuberculosis Drugs
Originally published on GBCHealth.org
Most TB drugs currently approved for treatment are 50+ years old and are required to be taken over a 6-month period to be effective. Compliance with such a long treatment regimen is a challenge, limiting drugs’ effectiveness and contributing to the rise in MDR-TB. As part of its MDR-TB Partnership, Eli Lilly and Company formed innovative partnerships with the Infectious Disease Research Institute (IDRI) and the Bill and Melinda Gates Foundation to discover new and more effective TB drugs. These partnerships draw on the expertise of private sector companies like Lilly and seek multi-sector solutions to accelerate progress in the fight against TB. Learn more about Lilly’s partnership with IDRI here.
Lilly TB Drug Discovery Initiative
Lilly launched its TB Drug Discovery Initiative in partnership with the Infectious Disease Research Institute (IDRI) and the National Institutes of Health (NIH/NIAID) in 2007. Formed as a public-private partnership with representatives from governments, philanthropic organizations, pharmaceutical companies, universities, and other research institutions, the initiative aims to fill the pipeline with new TB drugs.
Continue reading on GBCHealth.org >>
